36
Participants
Start Date
April 12, 2017
Primary Completion Date
November 5, 2017
Study Completion Date
December 5, 2017
ASN002
Daily dose of ASN002 for 28 days
Placebo Oral Tablet
Placebo for ASN002 for 28 days
Virginia Clinical Research, Inc., Norfolk
Dermatology Research Associates, Los Angeles
Olympian Clinical Research, Tampa
Forward Clinical Trials, Inc., Tampa
Dermatology Specialists Research, Louisville
Center for Clinical Studies, Ltd., LLP, Houston
Progressive Clinical Research, P.A., San Antonio
TCR Medical Corporation, San Diego
Center for Dermatology Clinical Research, Inc., Fremont
Innovaderm Research, Montreal
Lead Sponsor
Asana BioSciences
INDUSTRY